TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY

TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY

Objective: to study the time course of changes in laboratory biomarkers in patients with rheumatoid arthritis (RA) 2, 4, and 8 weeks after the initiation of tocilizumab (TCZ) therapy. Subjects and methods. Forty-two RA patients receiving two intravenous infusions of TCZ (8 mg/kg each) at a 4-week in...

ver descrição completa

Detalhes bibliográficos
Principais autores:	E N Aleksandrova, E Yu Panasyuk, A S Avdeyeva, A A Novikov, G V Lukina, M V Cherkasova, N V Klimova, E L Nasonov
Formato:	Artigo
Idioma:	Russian
Publicado em:	IMA PRESS LLC 2011-06-01
coleção:	Научно-практическая ревматология
Assuntos:	rheumatoid arthritis, interleukin-6 interleukin-6 receptors tocilizumab, erythrocyte sedimentation rate c-reactive protein, igm/iga rheumatoid factor anti-cyclic citrullinated peptide antibodies anti-modified citrullinated vimentin antibodies
Acesso em linha:	https://rsp.mediar-press.net/rsp/article/view/705

Registros relacionados

Impact of tocilizumab therapy on immunological parameters in patients with rheumatoid arthritis
por: Anastasia Sergeyevna Avdeyeva, et al.
Publicado em: (2012-06-01)

Bone destruction in rheumatoid arthritis: role of autoantibodies
por: Anastasia Sergeyevna Avdeyeva, et al.
Publicado em: (2013-06-01)

THE CLINICAL AND IMMUNOLOGICAL EFFECTS OF ANTI-B-CELL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
por: Elena Nikolayevna Aleksandrova, et al.
Publicado em: (2012-02-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
por: Maria Sergeevna Voronina, et al.
Publicado em: (2012-10-01)

Anti-modified citrullinated vimentin antibody: a novel biomarker associated with cardiac systolic dysfunction in patients with rheumatoid arthritis
por: Somayye Norouzi, et al.
Publicado em: (2020-08-01)

New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)
por: Evgeniy L'vovich Nasonov, et al.
Publicado em: (2010-05-01)

Correlation between anti-mutated citrullinated vimentin and bone turnover markers (CTX-1 and P1NP) in patients with rheumatoid arthritis in remission and low-disease activity
por: Tulus Widiyanto, et al.
Publicado em: (2022-08-01)

Methotrexate-induced changes in the concentration of antibodies to modified citrulnated vimentin in blood serum of patients with rheumatoid arthritis
por: Natal'ya Petrovna Shilkina, et al.
Publicado em: (2011-05-01)

Serum sirtuin-1 a potential marker in the diagnosis of rheumatoid arthritis
por: Liming Tan, et al.
Publicado em: (2023-12-01)

Specificity of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis
por: Nicole H. Trier, et al.
Publicado em: (2019-06-01)

Assessment of the Correlation between Disease Activity and Serum Biomarker Anti-MCV and IL6 in Iraqi Patients with Rheumatoid Arthritis
por: Dania A. Ali, et al.
Publicado em: (2024-10-01)

Rheumatoid factor and antibodies against cyclic citrullinated peptide in patients without rheumatoid arthritis
por: N. V. Bunchuk
Publicado em: (2023-01-01)

Antibodies to cyclic citrullinized peptide in rheumatoid arthritis
por: E N Aleksandrova, et al.
Publicado em: (2004-12-01)

Epitope Specificity of Anti-Citrullinated Protein Antibodies
por: Nicole H. Trier, et al.
Publicado em: (2017-03-01)

Identification of anti-citrullinated osteopontin antibodies and increased inflammatory response by enhancement of osteopontin binding to fibroblast-like synoviocytes in rheumatoid arthritis
por: Akio Umemoto, et al.
Publicado em: (2023-02-01)

The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis
por: Hui-Chun Yu, et al.
Publicado em: (2019-01-01)

Specificity of Anti-Citrullinated Protein Antibodies to Citrullinated α-Enolase Peptides as a Function of Epitope Structure and Composition
por: Ilaria Fanelli, et al.
Publicado em: (2021-07-01)

Antibodies against citrullinated proteins in relation to periodontitis with or without rheumatoid arthritis: a cross-sectional study
por: Pit Hui Lew, et al.
Publicado em: (2021-07-01)

Different clinical relevance of anti-citrullinated proteins antibodies in RA patients
por: A. S. Avdeeva, et al.
Publicado em: (2022-05-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
por: E. L. Nasonov, et al.
Publicado em: (2018-01-01)

Tocilizumab (Actemra)
por: Martin Sheppard, et al.
Publicado em: (2017-09-01)

Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production
por: Hisakata Yamada, et al.
Publicado em: (2020-04-01)

Evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis in comparison with other rheumatic diseases; a nephrology point of view
por: Alireza Sadeghi, et al.
Publicado em: (2017-04-01)

Type-III interferons and rheumatoid arthritis: Correlation between interferon lambda 1 (interleukin 29) and antimutated citrullinated vimentin antibody levels
por: Diana Castillo-Martínez, et al.
Publicado em: (2017-02-01)

Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in leprosy patients with articular involvement
por: S.L.E. Ribeiro, et al.
Publicado em: (2008-11-01)

RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN PATIENTS WITH PSORIATIC ARTHRITIS
por: V. V. Badokin, et al.
Publicado em: (2011-06-01)

When Autoantibodies Are Missing: The Challenge of Seronegative Rheumatoid Arthritis
por: Marino Paroli, et al.
Publicado em: (2023-10-01)

The diagnostic value of anti-cyclic citrullinated peptide antibodies (anti-CCP) in patients with rheumatoid arthritis
por: Damjanovska Ljubinka, et al.
Publicado em: (2007-01-01)

INVESTIGATION OF CANDIDATE GENE POLYMORPHISMS IN AN IMMUNE RESPONSE AS MARKERS FOR THE RISK OF DEVELOPING RHEUMATOID ARTHRITIS AND PRODUCING AUTOANTIBODIES
por: I. A. Guseva, et al.
Publicado em: (2016-03-01)

THE 2016 EULAR GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF EARLY ARTHRITIS
por: E. L. Nasonov
Publicado em: (2017-04-01)

The clinical aspect of overweight on rheumatoid arthritis and disease activity
por: Haitham Ahmed, et al.
Publicado em: (2019-06-01)

Evaluation of a new biomarker 14-3-3 Eta protein in diagnosis of rheumatoid arthritis
por: Lakshmi Deepika Yarlagadda, et al.
Publicado em: (2020-01-01)

Asthma and elevation of anti-citrullinated protein antibodies prior to the onset of rheumatoid arthritis
por: Alessandra Zaccardelli, et al.
Publicado em: (2019-11-01)

Cerebrovascular reactivity depending on rheumatoid factor and anticitrullinated protein antibody positivity in hypertensive patients with rheumatoid arthritis
por: N. V. Rebrova, et al.
Publicado em: (2022-07-01)

RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS
por: E Yu Panasyuk, et al.
Publicado em: (2011-08-01)

THE CLINICAL AND DIAGNOSTIC VALUE OF ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN EARLY JUVENILEARTHRITIS
por: S O Salugina, et al.
Publicado em: (2009-06-01)

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis
por: Noriyoshi Ogawa, et al.
Publicado em: (2019-01-01)

The diagnostic value of anti-cyclic citrullinated peptide antibodies, adenosine deaminase activity and other potential biomarkers for predicting and monitoring rheumatoid arthritis
por: Mehanović-Nikolić Jasminka, et al.
Publicado em: (2008-01-01)

An assessment of anti-citrullinated protein antibody in systemically healthy individuals with or without chronic periodontitis: A case–control study
por: Ankita Rajaram Yadav, et al.
Publicado em: (2020-01-01)

DIAGNOSTIC VALUE OF ANTI-PEPTIDYLARGININE DEIMINASE TYPE 4 (PADI-4) AND ANTI- CITRULLINATED PEPTIDE ANTIBODIES (ACCP) IN IRAQI PATIENTS WITH RHEUMATOID ARTHRITIS
por: Hassan J Hasony, et al.
Publicado em: (2014-06-01)